|The EDB(-) FN n/a (Catalog #MBS488255) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. The Anti-ED-B domain of fibronectin [G4] reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s ED-B domain of fibronectin can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Biacore, Western Blot (WB), Immunohistochemistry (IHC) Formalin. Researchers should empirically determine the suitability of the EDB(-) FN n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Recombinant monoclonal antibody to ED-B domain of fibronectin. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the phage display antibodyG4.
Immunogen: 2D-PAGE gel isolated human Extra-Domain containing fibronectin from lysate of human melanoma COLO-38 cells.
Antigen: ED-B domain of fibronectin
Antigen Description: 2D-PAGE gel isolated human Extra-Domain containing fibronectin from lysate of human melanoma COLO-38 cells. Chimeric Use Statement: This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques.
Publication Note: Describes generation, using phage display, of antibodies with subnanomolar affinity against markers of angiogenesis. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing EDB(-) FN are readily searchable from our website. Different antibodies against the same target such as EDB(-) FN may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.